In this study, participants will receive either rinatabart sesutecan or a treatment selected by their doctor, which may include medications such as doxorubicin or paclitaxel. These medications are administered through an IV infusion, a method where medicine is delivered directly into a vein through a small tube. The study aims to determine if the new drug works better than the standard options currently available for this condition.

During the course of the study, participants will undergo regular monitoring to track how the cancer responds to the medication and to observe any side effects. The researchers will look at how long the cancer remains stable without growing and the overall survival of the participants. This process involves continuous observation over several years to collect data on how the treatments affect the health and well-being of the individuals involved.

The purpose of the study is to see how well sacituzumab govitecan works compared to the other treatments in terms of slowing down the progression of the cancer and improving overall survival. Participants in the study will be randomly assigned to receive either sacituzumab govitecan or one of the other treatments. The study will involve regular visits to the clinic for treatment and monitoring, which will include tests like computed tomography (CT) or magnetic resonance imaging (MRI) to check the status of the cancer.

The study will continue for several years, with participants being closely monitored for any changes in their condition and any side effects from the treatments. The goal is to gather information that could help improve treatment options for people with endometrial cancer in the future.

The purpose of the study is to compare how well BNT323 works against the doctor’s choice of chemotherapy in stopping the cancer from getting worse or spreading. The study will measure how long patients live without their cancer growing or spreading, and how long patients survive overall. The study will also look at how many patients have their tumors shrink or disappear, how long these responses last, and what side effects occur with each treatment. Patients will be assigned to one treatment or the other by chance, similar to flipping a coin, and both the patients and their doctors will know which treatment is being given.

During the study, patients will receive their assigned treatment for up to six months, and they will be monitored regularly with scans and tests to see how their cancer is responding and to check for any side effects. The study will track whether the cancer grows or spreads, and doctors will use specific measurement criteria to evaluate the size and extent of the tumors throughout the treatment period. The information gathered will help determine whether BNT323 is more effective than standard chemotherapy for treating this type of recurring uterine cancer.

The purpose of the study is to determine the best dose of IMGN151 that can be safely given to patients and to see how well it works in treating these cancers. The study will be conducted in two main phases. In the first phase, different doses of IMGN151 will be tested to find the safest and most effective dose. In the second phase, the chosen dose will be given to more patients to further assess its effectiveness. Throughout the study, participants will receive IMGN151 through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

Participants in the study will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential benefits and risks of IMGN151 for women with these specific types of recurrent cancers. This research is important for developing new treatment options that could improve outcomes for patients facing these challenging conditions.

The purpose of the study is to understand the safety of using durvalumab with platinum-based chemotherapy, followed by durvalumab and olaparib as a first treatment option for patients with this type of cancer. The study will follow a specific course where patients will first receive the combination of durvalumab and chemotherapy. After this initial phase, patients will continue with durvalumab and olaparib. Some patients may receive a placebo instead of the active medications to help compare the effects.

Throughout the study, the health and progress of the participants will be closely monitored to gather information on how the treatment affects them. This includes looking at any side effects and how well the cancer responds to the treatment. The study aims to provide valuable insights into the potential benefits and risks of this treatment approach for endometrial cancer.

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the combination of lurbinectedin and dostarlimab in treating patients with advanced or recurrent endometrial cancer. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of lurbinectedin to use in combination with dostarlimab. In the second phase, they will assess how well this combination works in shrinking tumors in patients whose cancer has progressed after previous chemotherapy.

Participants in the study will receive the treatment and be monitored for any side effects and how well the cancer responds to the treatment. The study aims to provide valuable information on whether this combination of medications can be a beneficial treatment option for patients with advanced or recurrent endometrial cancer. The trial is expected to continue until 2026, with recruitment starting in 2024.

The purpose of the study is to determine the best treatment strategy for patients with this type of cancer. Participants will receive either a combination of dostarlimab and niraparib, niraparib alone, or standard chemotherapy. The study will be conducted in two phases. In the first phase, the goal is to select the most effective treatment strategy. In the second phase, the chosen strategy will be further evaluated for its effectiveness in treating the cancer.

Participants in the study will receive treatment over a period of time and will be monitored for their response to the treatment. The study aims to assess various outcomes, including how long patients live without the cancer getting worse and their overall survival. The safety and tolerability of the treatments will also be evaluated to ensure that they are safe for patients. This study is an important step in finding better treatment options for those affected by metastatic or recurrent endometrial or ovarian carcinosarcoma.

Participants in the study will be randomly assigned to receive either Selinexor or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased. The treatment will be administered orally, and the maximum treatment period is four months. The study will monitor the participants’ health and any changes in their condition over time.

The main goal of the study is to assess the progression-free survival, which refers to the length of time during and after treatment that a patient lives with the disease without it getting worse. Other aspects being evaluated include the time to first and second subsequent therapies, overall survival, and the safety and tolerability of the treatment. Participants’ quality of life will also be assessed using specific questionnaires. The study aims to provide valuable information on the potential benefits of Selinexor for patients with advanced or recurrent endometrial cancer.